03:57 PM EDT, 03/26/2025 (MT Newswires) -- Health care stocks declined Wednesday afternoon, with the NYSE Health Care Index down 0.6% and the Health Care Select Sector SPDR Fund (XLV) shedding 0.4%.

The iShares Biotechnology ETF (IBB) fell 1.4%.

In corporate news, federal prosecutors are investigating a claim brought by GSK (GSK) that Pfizer ( PFE ) delayed announcing the success of its COVID vaccine in 2020 until after that year's election, The Wall Street Journal reported. GSK shares fell 0.5%, and Pfizer ( PFE ) shed 1.4%.

Novo Nordisk's ( NVO ) settlement on the out-of-pocket price cap of insulin for Minnesota residents at $35 per month for the next five years was approved by a federal court in New Jersey, Bloomberg reported, citing a court document. Novo shares were retreating 2.6%.

OSR (OSRH) shares soared 136% after its Vaximm unit said final data from a phase 2a trial showed its vaccine candidate, VXM01, plus avelumab could "offer meaningful clinical benefit" in people with recurrent glioblastoma, a type of aggressive brain cancer.

Jaguar Health ( JAGX ) shares fell 5% after the company struck deals to sell up to nearly $3.5 million in convertible promissory notes to Chief Executive Officer Lisa Conte, three board members, seven other senior executives and selected investors.